REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2015

Dec 18, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2015-12-16

Reporting Person: Powchik Peter (SVP Clinical Development & Reg)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-12-16	Common Stock	M	1921.0	$52.03	Acquired	17742	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-12-16	Incentive Stock Option (right to buy)	$52.03	M	1921.0	Disposed	2021-12-16	Common Stock (1921)	Direct
2015-12-16	Non-Qualified Stock Option (right to buy)	$555.67	A	25000.0	Acquired	2025-12-16	Common Stock (25000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12890	Indirect
Common Stock	1652	Indirect

Footnotes

F1: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.